Wall Street brokerages expect CELYAD SA/ADR (NASDAQ:CYAD) to report earnings of ($1.88) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for CELYAD SA/ADR’s earnings. The firm is scheduled to announce its next quarterly earnings results on Thursday, March 28th.
On average, analysts expect that CELYAD SA/ADR will report full-year earnings of ($3.85) per share for the current financial year, with EPS estimates ranging from ($5.06) to ($3.03). For the next financial year, analysts forecast that the company will report earnings of ($4.38) per share, with EPS estimates ranging from ($4.86) to ($4.09). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for CELYAD SA/ADR.
A number of equities analysts have issued reports on CYAD shares. Zacks Investment Research raised shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a research note on Tuesday, October 23rd. William Blair started coverage on shares of CELYAD SA/ADR in a research note on Tuesday, October 30th. They issued an “outperform” rating on the stock. Piper Jaffray Companies reduced their price objective on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating on the stock in a research note on Monday, November 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of CELYAD SA/ADR in a research note on Monday, November 12th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. CELYAD SA/ADR currently has an average rating of “Buy” and an average target price of $44.20.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of CELYAD SA/ADR by 1,109.0% during the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after purchasing an additional 5,545 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of CELYAD SA/ADR by 2.8% during the third quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock worth $16,374,000 after acquiring an additional 17,160 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of CELYAD SA/ADR during the second quarter worth $582,000. 7.70% of the stock is currently owned by institutional investors.
Shares of CYAD traded up $0.45 during mid-day trading on Friday, hitting $20.58. 275 shares of the company traded hands, compared to its average volume of 3,635. CELYAD SA/ADR has a one year low of $15.36 and a one year high of $42.87. The stock has a market capitalization of $210.58 million, a P/E ratio of -5.79 and a beta of 1.86.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: What is a Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.